New study tracks fabry drug Elfabrio's Real-World impact

NCT ID NCT06663358

Recruiting now Disease control Sponsor: Chiesi Farmaceutici S.p.A. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows about 100 adults with Fabry disease who are taking or planning to take the medication Elfabrio. Researchers will monitor kidney function, heart health, and disease markers over time to see how well the drug works and if any side effects occur. The goal is to understand the drug's real-world safety and effectiveness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FABRY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Fabry disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

FABRY DISEASE

Contacts and locations

Locations

Emory University School of Medicine
RECRUITING

Atlanta, Georgia, 30322, United States
General Hospital Slovenj Gradec
RECRUITING

Slovenj Gradec, 2380, Slovenia
Infusion Associates
RECRUITING

Grand Rapids, Michigan, 49525, United States
Lysosomal & Rare Disorder Research & Treatment Center (LRDRTC)
RECRUITING

Fairfax, Virginia, 22030, United States
Northwestern University - Feinberg School of Medicine - Ann & Robert H. Lurie Children's Hospital of Chicago
RECRUITING

Chicago, Illinois, 60611, United States
Salford Royal
RECRUITING

Salford, Greater Manchester, M6 8HD, United Kingdom
The Royal Free Hospital
RECRUITING

London, NW3 2QG, United Kingdom
University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital
RECRUITING

Edgbaston, Birmingham, B152TH, United Kingdom
University of Alabama at Birmingham
RECRUITING

Birmingham, Alabama, 35294, United States
University of Iowa Hospitals and Clinics
RECRUITING

Iowa City, Iowa, 52242, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.